Clinical trial

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

NCT00322452

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-03-01

PhasePHASE3

Study timeline

Study start (unknown)2006-03-01Date precision: month

Registry last updated2013-11-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Interventions

GefitinibDRUG · verified · RxNorm: gefitinib

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

TaipeiTaiwan1 GuangzhouGuangdong, China1 BeijingChina1 ShanghaiChina1 NanjingJiangsu, China1 SingaporeSingapore1 Kaohsiung CityTaiwan1 WuhanHubei, China1 Hong KongHong Kong1 BangkokThailand1 TaoyuanTaiwan1 ChengduChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00322452 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.